Global menu

Our global pages

Close

Securing a healthy outlook for leading probiotic supplements provider

  • Global

    29-06-2018

    Eversheds Sutherland advises on the £185m sale of Probiotics International Limited to Archer Daniels Midland Company

    Eversheds Sutherland has advised the shareholders of Probiotics International Limited (PIL), a leading provider of probiotic supplements for human and animal use, on its proposed £185m sale to Archer Daniels Midland Company (ADM).

    With sales into more than 60 countries, UK-based PIL’s products include the popular Protexin brand of probiotic supplements along with contract-manufactured products.

    US-based ADM is one of the world’s largest providers of human and animal nutrition solutions with approximately 31,000 employees serving customers in more than 170 countries.

    The Eversheds Sutherland team was led by corporate Partner Antony Walsh and comprised: Julia Chirnside, Principal Associate (pensions), Alex McCarney, Senior Associate (corporate), Associate Kathryn Dodds (corporate) and Associate Alex Lane (pensions).

    The team provided advice on all aspects of the deal. Subject to customary regulatory approvals, the all-cash transaction is expected to complete in the coming weeks.

    Antony Walsh commented:

    “This is a seminal moment in the history of PIL and one that is strategically significant to the ongoing growth and success of its business. We’re delighted to have advised.”

    John Melling, Chairman, PIL, commented:

    “This transaction helps to reinforce the foundations of an already successful business, providing a solid platform from which to continue our growth and development. The personal commitment displayed by the Partner-led Eversheds Sutherland team to the success of this deal was evident throughout. Their technical excellence, experience and level of capability were second to none. We’re delighted.”

    For more information on Eversheds Sutherland, visit eversheds-sutherland.com

    Disclaimer

    This information is for guidance purposes only and should not be regarded as a substitute for taking legal advice. Please refer to the full terms and conditions on our website.

    < Go back

    Print Friendly and PDF
    Register to receive regular updates via email.